Business Context and Reporting Period
This Form 8-K Current Report was filed by Benitec Biopharma Inc. on September 13, 2023. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved base salary increases for two key executives, effective October 1, 2023:
- Dr. Jerel Banks (Executive Chairman and CEO): New base salary of $655,200.
- Megan Boston (Executive Director): New base salary of $350,784 (converted from AUD using an October 13, 2023 rate of 0.64 USD/AUD).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of the salary increases (October 1, 2023) against the company's fiscal calendar.
- Confirm the total annual compensation impact on the company's operating expenses.
- Review the company's cash position to assess the ability to fund increased executive compensation.
- Check for any related proxy statements or shareholder approvals required for these compensation changes.